Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grand Pharmaceutical GroupFRA:MX6A +1.80%86 Dividend Yield % is 3.35% as of Jul. 17, 2026, which is 30% above its 10-year median of 2.57. GuruFocus rates FRA:MX6A with a GF Score™ of 86/100 and a GF Value™ of €0.63 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 514 Drug Manufacturers companies, Grand Pharmaceutical Group ranks better than 72.96% on this metric.
During the past 3 years, the average Dividends Per Share Growth Rate was 33.20% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 25.00% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Grand Pharmaceutical Group was 33.20% per year. The lowest was 8.60% per year. And the median was 23.30% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Grand Pharmaceutical Group (FRA:MX6A) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:MX6A vs ZTS, UTHR: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's Dividend Yield % falls into.
Grand Pharmaceutical Group Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Grand Pharmaceutical Group Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
HKD 0.169000
2026-06-12
2026-06-16
2026-06-30
Cash Dividend
annually
HKD:EUR 0.110690
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group (FRA:MX6A) has a Dividend Yield % of 3.35% as of Jul. 17, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Grand Pharmaceutical Group and its competitors. This is 30% above median its historical median of 2.57. Over the past decade, Grand Pharmaceutical Group's Dividend Yield % has ranged from 1.04 to 6.18. According to the industry distribution chart, Grand Pharmaceutical Group ranks #139 out of 514 companies in the Drug Manufacturers industry, placing it in the top 27%.
Is Grand Pharmaceutical Group's Dividend Yield % too high?
Grand Pharmaceutical Group's current Dividend Yield % of 3.35% is 30% above median its 10-year median of 2.57. Over the past 10 years, this metric has ranged from a low of 1.04 to a high of 6.18. The Drug Manufacturers industry median Dividend Yield % is 1.95. Grand Pharmaceutical Group's value of 3.35% is 72.2% above this industry median. Based on the distribution chart, Grand Pharmaceutical Group ranks #139 out of 514 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grand Pharmaceutical Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #139 out of 514 companies for Dividend Yield %. This puts Grand Pharmaceutical Group in the upper half of its industry. The industry median Dividend Yield % is 1.95. Grand Pharmaceutical Group's value of 3.35% is 72.2% above this benchmark. Historically, Grand Pharmaceutical Group's own Dividend Yield % has ranged from 1.04 to 6.18 over the past decade. While the company's 10-year median is 2.57 vs. the industry median of 1.95, Grand Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.95, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current Dividend Yield % of 3.35% is 72.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current Dividend Yield % is 3.35%, which is 30% above median its own 10-year median of 2.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Grand Pharmaceutical Group (FRA:MX6A) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.63, compared to a current price of €0.57 — trading 10.3% below its estimated fair value. The current Dividend Yield % is 3.35%, which is 30% above median its 10-year median of 2.57 and 72.2% above the Drug Manufacturers industry median of 1.95. Grand Pharmaceutical Group's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Grand Pharmaceutical Group (FRA:MX6A), the current Dividend Yield % is 3.35% as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grand Pharmaceutical Group (FRA:MX6A) Overvalued in 2026?
Based on GuruFocus' analysis, Grand Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.57 is trading 10.3% below its estimated GF Value™ of €0.63.
GuruFocus considers Grand Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for FRA:MX6A:
Dividend Yield %: 3.35% (30% above median its 10-year median of 2.57)
GF Value™: €0.63 vs. price of €0.57 (10.3% below fair value)
Industry Position: 72.2% above the Drug Manufacturers median (#139 of 514)
No single metric tells the full story. See the FRA:MX6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
86GF Score
Get the complete analysis for FRA:MX6A
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MX6A has been successfully added to your 
